You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Moodys
Harvard Business School
Mallinckrodt
Merck

Last Updated: February 16, 2020

DrugPatentWatch Database Preview

Etanercept - Biologic Drug Details


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for etanercept

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Nanfang Hospital of Southern Medical UniversityPhase 4
Lawson Health Research InstitutePhase 4
Academic Medical Organization of Southwestern OntarioPhase 4

See all etanercept clinical trials

Recent Litigation for etanercept

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC.2019-12-31
CELGENE CORPORATION v. HETERO LABS LIMITED2019-07-16
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12

See all etanercept litigation

PTAB Litigation
PetitionerDate
Dr. Reddy's Laboratories, Inc.2018-08-03
2014-11-06
2013-08-15

See all etanercept litigation

Pharmacology for etanercept

Company Disclosures: US Patents for etanercept

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2012-03-07 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2014-02-25 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2009-09-05 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for etanercept

These patents were identified by searching patent claims

Supplementary Protection Certificates for etanercept

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2041177/01 Switzerland   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66424 20.04.2018
17/056 Ireland   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
00728 Netherlands   Start Trial PRODUCT NAME: IBRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 20141021
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Mallinckrodt
Dow
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.